Revenue Estimates Analysis: Galena Biopharma, Inc. (NASDAQ:GALE)


Galena Biopharma, Inc. (NASDAQ:GALE) reported its last earnings on Aug 09 AMC (BMO = before market open, AMC= after market close). The company will report its next earnings on Nov 7 – Nov 11 (Est.). The company reported the earnings of $0.03/Share in the last quarter where the estimated EPS by analysts was $-0.06/share. The difference between the expected and actual EPS was $0.09/share, which represents an Earnings surprise of 150%.

Many analysts are providing their Estimated Earnings analysis for Galena Biopharma, Inc. and for the current quarter 3 analysts have projected that the stock could give an Average Earnings estimate of $-0.04/share. These analysts have also projected a Low Estimate of $-0.06/share and a High Estimate of $-0.03/share.

Some buy side analysts are also providing their Analysis on Galena Biopharma, Inc., where 1 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 2 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. 3 Analysts reported that the Price Target for Galena Biopharma, Inc. might touch $2 high while the Average Price Target and Low price Target is $1.13 and $0.4 respectively.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. Galena Biopharma, Inc. got Downgrade on 29-Jun-16 where investment firm Raymond James Downgrade the stock from Outperform to Mkt Perform.

Galena Biopharma, Inc. closed its last trading session at $0.4 with the gain of 2.05%. The Market Capitalization of the company stands at 84.66 Million. The Company has 52-week high of $2.49 and 52-week low of $0.28. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -5.43% where SMA50 and SMA200 are -30.08% and -64.05% respectively. The Company Touched its 52-Week High on Jun 20, 2016 and 52-Week Low on Jun 29, 2016.

The Relative Volume of the company is 0.32 and Average Volume (3 months) is 8.04 million. Galena Biopharma, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -64%. The Return on Equity (ROE) value stands at -248.2%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, Galena Biopharma, Inc. currently shows a Weekly Performance of -3.98%, where Monthly Performance is -12.33%, Quarterly performance is -80.89%, 6 Months performance is -59.26% and yearly performance percentage is -75.1%. Year to Date performance value (YTD perf) value is -72.56%. The Stock currently has a Weekly Volatility of 4.61% and Monthly Volatility of 7.02%.